TY - JOUR
T1 - Effects of corneal nerve density on the response to treatment in dry eye disease
AU - Kheirkhah, Ahmad
AU - Dohlman, Thomas H.
AU - Amparo, Francisco
AU - Arnoldner, Michael A.
AU - Jamali, Arsia
AU - Hamrah, Pedram
AU - Dana, Reza
N1 - Publisher Copyright:
© 2015 American Academy of Ophthalmology.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Purpose To evaluate whether levels of corneal subbasal nerve fiber length (SNFL) in dry eye disease (DED) could prognosticate the level of improvement in signs and symptoms after treatment. Design Phase IV, double-masked, randomized clinical trial. Participants Sixty patients with meibomian gland dysfunction-associated DED and 27 age-matched controls. Methods Patients with DED were randomized to receive topical artificial tears, loteprednol etabonate 0.5%, or loteprednol etabonate 0.5%/tobramycin 0.3% twice daily for 4 weeks. At baseline, in vivo confocal microscopy of central cornea was performed in both eyes. Patients with DED were divided into 2 subgroups: those with low baseline SNFL and those with near-normal baseline SNFL for this purpose (the cutoff point: the mean SNFL in controls minus 2 standard deviations). Clinical signs and symptoms at baseline and after 4 weeks of treatment were compared between the subgroups with low and near-normal SNFL for all therapeutic groups. Main Outcome Measures Symptom questionnaires, corneal fluorescein staining (CFS), conjunctival staining with lissamine green, tear break-up time, Schirmer's test, and SNFL. Results In patients with DED, baseline SNFL (17.06±5.78 mm/mm2) was significantly lower than in controls (23.68±3.42 mm/mm2, P = 0.001). In the artificial tear and loteprednol groups, although no significant improvement in any sign or symptom was noted in patients with low baseline SNFL (<16.84 mm/mm2), subjects with near-normal baseline SNFL (≥16.84 mm/mm2) showed significant improvement in both symptoms and CFS score (all P < 0.05). In the loteprednol/tobramycin group, no significant change was evident for any sign or symptom in either subgroup of low or near-normal baseline SNFL. Conclusions Significant improvements in CFS and patient symptomatology after DED treatment were evident only in the subgroup with near-normal corneal SNFL. Consideration of SNFL may assist in explaining the variability of patients' response to DED therapy.
AB - Purpose To evaluate whether levels of corneal subbasal nerve fiber length (SNFL) in dry eye disease (DED) could prognosticate the level of improvement in signs and symptoms after treatment. Design Phase IV, double-masked, randomized clinical trial. Participants Sixty patients with meibomian gland dysfunction-associated DED and 27 age-matched controls. Methods Patients with DED were randomized to receive topical artificial tears, loteprednol etabonate 0.5%, or loteprednol etabonate 0.5%/tobramycin 0.3% twice daily for 4 weeks. At baseline, in vivo confocal microscopy of central cornea was performed in both eyes. Patients with DED were divided into 2 subgroups: those with low baseline SNFL and those with near-normal baseline SNFL for this purpose (the cutoff point: the mean SNFL in controls minus 2 standard deviations). Clinical signs and symptoms at baseline and after 4 weeks of treatment were compared between the subgroups with low and near-normal SNFL for all therapeutic groups. Main Outcome Measures Symptom questionnaires, corneal fluorescein staining (CFS), conjunctival staining with lissamine green, tear break-up time, Schirmer's test, and SNFL. Results In patients with DED, baseline SNFL (17.06±5.78 mm/mm2) was significantly lower than in controls (23.68±3.42 mm/mm2, P = 0.001). In the artificial tear and loteprednol groups, although no significant improvement in any sign or symptom was noted in patients with low baseline SNFL (<16.84 mm/mm2), subjects with near-normal baseline SNFL (≥16.84 mm/mm2) showed significant improvement in both symptoms and CFS score (all P < 0.05). In the loteprednol/tobramycin group, no significant change was evident for any sign or symptom in either subgroup of low or near-normal baseline SNFL. Conclusions Significant improvements in CFS and patient symptomatology after DED treatment were evident only in the subgroup with near-normal corneal SNFL. Consideration of SNFL may assist in explaining the variability of patients' response to DED therapy.
UR - http://www.scopus.com/inward/record.url?scp=84925346811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925346811&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2014.11.006
DO - 10.1016/j.ophtha.2014.11.006
M3 - Article
C2 - 25542519
AN - SCOPUS:84925346811
SN - 0161-6420
VL - 122
SP - 662
EP - 668
JO - Ophthalmology
JF - Ophthalmology
IS - 4
ER -